Healthium Medtech Acquisition, Valuation, Funding & Investors

SEEGENE Inc is engaged in the healthcare sector. The Korean firm specializes in developing upgraded technology for accurate diagnosis of various diseases. Its products include pathogen inspection solutions such as respiratory, gastrointestinal, tuberculosis and meningitis pathogens.

Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.

Wilson Wolf Corporation is a medical device manufacturer headquartered in Eden Prairie, Minnesota, producing gas-permeable cell culture flasks and bioreactors for mammalian cell expansion in applications like monoclonal antibody production, stem cell therapy, and tissue engineering. Established in 1998, the company supplies platforms used by researchers at Mayo Clinic and universities for immunotherapy and diabetes research.

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.

Bide Pharmatech Co Ltd is engaged in the research and development, design, production and sales of drug molecular building blocks.

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.

BioRender is a Toronto-headquartered web platform enabling scientists in pharmaceuticals and life sciences to create publication-ready figures and illustrations. Launched in 2018, it hosts over 50,000 customizable icons across biology, chemistry, and medicine, used by more than 10 million researchers at institutions like Harvard, Pfizer, and Novartis. The tool supports collaborative editing, exports in vector formats for journals such as Nature and Cell, and integrates with lab notebooks, streamlining communication with consistent visual standards.

Synchron is a neurotechnology company advancing brain-computer interfaces through its endovascular Stentrode device. Delivered via catheter to the brain's blood vessels, it records neural signals for controlling external devices like prosthetics and computers. Brooklyn-headquartered, Synchron conducts clinical trials in Australia and the United States targeting paralysis patients.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

RefleXion Medical is a developer of biology-guided radiotherapy systems for cancer treatment. Hayward-headquartered in California, RefleXion's X1 machine delivers stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT platform uses real-time PET imaging to target metastatic tumors with subsecond precision. RefleXion raised over $380 million in funding from investors including Sofinnova and Temasek.

LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.

AcuityMD is a software platform that aggregates clinical utilization data to accelerate medical device commercialization for orthopedics and spine companies. Boston-headquartered, it analyzes procedure volumes and surgeon preferences from electronic health records across U.S. hospitals. The platform equips sales teams with market intelligence on over 10 million procedures, enabling targeted account planning and evidence-based launches.

ZSPepLib is a peptide drug discovery platform company established in January 2017 and based in Zhuzhou, Hunan province, China. The firm specializes in large-scale peptide libraries for lead compound screening, custom peptide synthesis, and R&D services targeting therapeutic development in oncology and metabolic diseases.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.